As rkrw would say, you’re over-analyzing the situation. I’m certain that all of the patents admitted by the Court in Teva’s lawsuit against NVS/MNTA expire on 5/24/14. Even Teva never claimed otherwise—they merely threw a curveball in their 9/21/10 PR on the Mylan suit, perhaps intending to mislead the sell-side analysts who cover this space into assuming that Copaxone was protected until Sep 2015.
As far as I’m concerned, this topic does not warrant further message-board bandwidth unless there’s a new ruling from the Court that changes the landscape.
Market Data 
Markets 
AI
